Top Page
China Medical System Holdings
(0867)
China Medical System Holdings (0867) vs. iShares MSCI Hong Kong ETF (EWH)
China Medical System Holdings Business Overview & Revenue Model
China Medical System Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.86B | 7.47B | 8.01B | 9.15B | 8.34B | 6.95B |
| Gross Profit | 5.62B | 5.42B | 6.11B | 7.04B | 6.25B | 5.13B |
| EBITDA | 2.30B | 2.31B | 2.92B | 3.76B | 3.70B | 3.05B |
| Net Income | 1.65B | 1.62B | 2.40B | 3.26B | 3.02B | 2.53B |
Balance Sheet | ||||||
| Total Assets | 18.94B | 18.05B | 17.73B | 17.75B | 15.81B | 12.70B |
| Cash, Cash Equivalents and Short-Term Investments | 5.97B | 5.87B | 6.14B | 5.87B | 4.36B | 2.67B |
| Total Debt | 747.60M | 860.74M | 1.30B | 1.81B | 1.71B | 600.16M |
| Total Liabilities | 1.77B | 1.64B | 2.17B | 3.02B | 2.96B | 1.60B |
| Stockholders Equity | 17.02B | 16.31B | 15.52B | 14.59B | 12.75B | 11.03B |
Cash Flow | ||||||
| Free Cash Flow | 493.64M | 812.64M | 2.18B | 3.03B | 2.31B | 2.35B |
| Operating Cash Flow | 952.52M | 1.27B | 2.50B | 3.55B | 2.49B | 2.69B |
| Investing Cash Flow | -439.01M | -615.10M | -442.28M | -1.18B | -1.52B | -353.82M |
| Financing Cash Flow | -983.08M | -1.26B | -2.13B | -1.40B | -258.39M | -1.03B |
China Medical System Holdings Technical Analysis
China Medical System Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $44.96B | 9.63 | 7.86% | 7.07% | 1.13% | -13.53% | |
74 Outperform | HK$32.72B | 11.94 | 14.91% | 3.87% | -0.45% | 9.00% | |
73 Outperform | HK$31.09B | 14.75 | 12.65% | 3.17% | 10.56% | -13.58% | |
68 Neutral | €31.10B | 10.23 | 5.90% | 2.93% | ― | ― | |
65 Neutral | $32.86B | 18.37 | 10.01% | 2.20% | 11.78% | 19.06% | |
64 Neutral | HK$24.03B | 6.70 | 21.02% | 5.03% | 0.39% | 4.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
China Medical System Holdings Corporate Events
China Medical System Holdings has announced that its subsidiary, Dermavon Holdings, has had its new drug application for MG-K10, a long-acting anti-IL-4Rα humanized monoclonal antibody injection, accepted by China’s National Medical Products Administration. This drug, intended for treating moderate-to-severe atopic dermatitis, has shown promising results in clinical trials and is expected to enhance patient adherence due to its four-week dosing schedule. If approved, MG-K10 will enrich the company’s dermatological product portfolio and strengthen Dermavon’s market competitiveness.
China Medical System Holdings Limited has entered into a Distribution Agreement with Novartis Pharma Services AG for the exclusive rights to distribute Lucentis® and Beovu® in mainland China. This agreement enhances the company’s portfolio in the ophthalmic drug market, allowing it to capitalize on the growing demand for anti-VEGF drugs in China, projected to expand significantly by 2030. The inclusion of Lucentis®, a well-established treatment for ocular neovascular diseases, and Beovu®, a novel treatment for diabetic macular edema, strengthens the company’s position in the ophthalmic sector and offers potential growth opportunities.
China Medical System Holdings announced that its subsidiary, Dermavon Holdings, received approval from the National Medical Products Administration to conduct Phase III clinical trials for MG-K10, a long-acting anti-IL-4Rα monoclonal antibody, for treating chronic spontaneous urticaria (CSU). This development positions MG-K10 as a potential best-in-class treatment option, enhancing the company’s product portfolio and offering new therapeutic options for patients in China. The approval is expected to strengthen the company’s market position and provide a synergistic effect with its existing dermatological products.
China Medical System Holdings Limited has announced that its innovative drug, CMS-D002, has received approval from the National Medical Products Administration for clinical trials targeting uterine fibroids. This approval marks a significant step in expanding the drug’s indications beyond endometriosis, potentially enhancing the company’s product portfolio and strengthening its position in the gynecological treatment market. CMS-D002, a GnRH receptor antagonist, offers a promising treatment option without the flare-up effect seen in other treatments, potentially meeting the unmet clinical demand for effective and safe uterine fibroid therapies.
China Medical System Holdings Limited announced positive results from a Phase 3 clinical trial of ruxolitinib cream for treating mild to moderate atopic dermatitis in Chinese patients. The trial demonstrated significant efficacy and safety, with a higher proportion of patients achieving improvement compared to placebo. The company is advancing the new drug application process in China, potentially impacting the treatment landscape for atopic dermatitis, a condition affecting millions in the country.
China Medical System Holdings Limited has entered into exclusive collaboration agreements with Chongqing Genrix Biopharmaceutical Co., Ltd. for two innovative biologic products: Vecantoxatug Injection, aimed at passive immunization against tetanus, and Silevimig Injection, targeting rabies virus exposure. These agreements grant the company commercialization rights in mainland China and licensing rights across the Asia-Pacific, Middle East, and North Africa regions. The collaboration enhances the company’s portfolio in passive immunization, potentially offering advanced therapeutic options with improved safety and accessibility, thus strengthening its market position in the biopharmaceutical sector.